The Pharma Navigator back issues.
Issue 9
Google Releases AlphaFold 3, Biopharma Continues to Fuel CDMO Growth
If you're tired of hearing about the latest advances in AI and how they are poised to revolutionize science, we are too. But just last week, some exciting updates emerged from the most successful scientific AI tool yet…
Issue 8
Growth forecasts for orphan drugs slow and AZ’s CEO calls out Europe
A report recently published by Evaluate titled “Are Orphan Drugs Losing Their Sparkle” might sound apprehensive, but it highlights why pharma companies can still expect plenty of promise and activity within the orphan drug sector…
Issue 7
Will biosimilars threaten Big Pharma dominance? Why is generic uptake so low?
As the industry looks to find more effective ways to manage the rising burden of genetic, autoimmune, rare diseases, and cancers, the next 10 years could be significant for companies with an interest in biologics drug products…
Issue 6
What's next for mRNA after COVID-19, and will there be any CDMOs left?
The COVID-19 pandemic brought its fair share of disruption and uncertainty; propelling biopharma-related topics into the public consciousness. The development of mRNA vaccines took centre stage. Investigated as potential treatments since the 1990s, companies like Moderna gave them top billing…
Issue 5
Will 2024 see more money for Biotech? What Medicare will mean for drug pricing, and on drugs losing exclusivity
Are we on the brink of a biotech renaissance? After a period of recalibration, the industry is showing signs of revival…
Issue 4
Is Changing Cannabis Legislation a Promising Sign for Pharmaceutical Cannabinoids?
Legalisation of cannabis has been a hot topic for many years already, and it doesn’t look like that is set to change…
Issue 3
ADC funding for cancer, investment for AI discovery platform & Super Bowl commercials you might have missed
Opioids have long been used for the treatment of pain management, yet their overuse and abuse causes real issues across global societies…
Issue 2
They say ‘you can’t outrun a bad diet,’ and you’ll be hard-pushed to stay ahead of news about weight-loss drugs too
You are probably well aware of the enthusiasm around weight-loss drugs; Wegovy, Ozempic and Zepbound to name a few. Their performance has raised interest in those who are considering using them for their same effects as lifestyle drugs…
Issue 1
In our inaugural issue, we cover just some of the news stories that appeared in time for CPHI in Barcelona
Did we see ripples of cautious optimism from the JP Morgan conference? The industry is certainly ready for the small uplift in last year’s FDA approvals, and for biotech dealmaking to continue.
Why not sign up for our future email newsletters? Sign up here.